Decentralized Clinical Trial Software Development

A DCT reduces or eliminates the need for participants to visit a physical site — enrollment, consent, assessments, and data collection all happen remotely, through web, mobile, wearables, or in-home visits. Most real-world studies land somewhere on a spectrum between fully site-based and fully decentralized, which is why we build hybrid architectures as often as fully remote ones.

Most studies benefit from a hybrid approach — some assessments remote, some still requiring an in-person visit. We design the architecture around what your protocol actually needs, not a one-size-fits-all remote-everything model.

Scheduled reminders, simple mobile-first data capture, and visible progress tracking all reduce dropout. We also build coordinator tooling to flag disengaged participants early, before they're lost to follow-up entirely.

Yes — a DCT platform is really the delivery layer that connects to your data capture, outcome assessment, and registry systems underneath. We build these as connected pieces, whether that means integrating with your existing systems or building all of it as one unified platform.

We build in localization, region-specific consent and privacy handling, and role-based access for coordinators across sites, so the same platform supports studies running in multiple countries at once.

PHI-safe handling with built-in hide/show controls, role-based access, and full audit trails are core to the architecture, not an add-on — the same standard we hold for in-clinic data.

The architecture is built to be extensible — new assessment modules, instruments, or device integrations can be added without rebuilding the platform or disrupting an active study.

Yes. We've built this exact scaling story before — the same architecture now runs 8 active studies across two countries and two disease areas, added incrementally rather than rebuilt each time.